
Medigus Ltd. MDGS
Annual report 2024
added 02-21-2026
Medigus Ltd. Total Assets 2011-2026 | MDGS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Medigus Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.5 M | 63.9 M | 97.7 M | 59.7 M | - | 13.3 M | 11.2 M | 7.21 M | 4.72 M | 47.4 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 97.7 M | 4.72 M | 38.1 M |
Quarterly Total Assets Medigus Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 59.7 M | - | 63.6 M | - | 32.3 M | - | 17.9 M | - | 13.3 M | - | 9.66 M | - | 11.2 M | - | 4.8 M | - | 7.21 M | - | - | - | 4.72 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 63.6 M | 4.72 M | 22.5 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aziyo Biologics
AZYO
|
43.4 M | - | 1.37 % | $ 20.5 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | ||
|
Bruker Corporation
BRKR
|
5.81 B | $ 38.78 | -1.25 % | $ 5.78 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
132 M | - | - | $ 10.2 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Cognyte Software Ltd.
CGNT
|
498 M | $ 8.15 | 4.22 % | $ 585 M | ||
|
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | ||
|
AdaptHealth Corp.
AHCO
|
4.32 B | $ 9.69 | 3.09 % | $ 1.31 B | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
86.1 M | $ 4.15 | 4.01 % | $ 155 M | ||
|
Electromed
ELMD
|
53.8 M | $ 24.26 | 1.17 % | $ 205 M | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 43.13 | -0.43 % | $ 1.34 B | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
FONAR Corporation
FONR
|
199 M | $ 18.51 | 0.05 % | $ 121 M | ||
|
AxoGen
AXGN
|
222 M | $ 29.17 | -2.21 % | $ 1.34 B | ||
|
Apyx Medical Corporation
APYX
|
79.2 M | $ 3.31 | 4.42 % | $ 115 M | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
Accuray Incorporated
ARAY
|
470 M | $ 0.53 | 0.68 % | $ 54.5 M | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
Cytosorbents Corporation
CTSO
|
47.4 M | $ 0.79 | -1.24 % | $ 43 M | ||
|
Align Technology
ALGN
|
6.21 B | $ 183.14 | 0.27 % | $ 13.7 B | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
Inari Medical
NARI
|
504 M | - | - | $ 4.23 B | ||
|
Butterfly Network
BFLY
|
256 M | $ 3.99 | 7.7 % | $ 845 M | ||
|
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
86.7 B | $ 113.59 | 0.01 % | $ 198 B | ||
|
NuVasive
NUVA
|
2.22 B | - | - | $ 2.07 B | ||
|
Nevro Corp.
NVRO
|
554 M | - | - | $ 217 M | ||
|
InMode Ltd.
INMD
|
766 M | $ 13.58 | -0.18 % | $ 878 M | ||
|
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 72.75 | -1.49 % | $ 108 B | ||
|
IRadimed Corporation
IRMD
|
98.3 M | $ 105.22 | 0.89 % | $ 1.33 B | ||
|
IRIDEX Corporation
IRIX
|
34.4 M | $ 1.42 | -0.7 % | $ 22.9 M | ||
|
Helius Medical Technologies
HSDT
|
7.69 M | $ 2.31 | 16.67 % | $ 1.4 M | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 13.05 | 0.23 % | $ 1.96 B | ||
|
Edwards Lifesciences Corporation
EW
|
13.7 B | $ 85.73 | 0.55 % | $ 50.1 B |